QualityStocksNewsBreaks Archives - Page 1004 of 1635

WednesdayJan 13, 2021 11:53 am

QualityStocksNewsBreaks – SRAX (NASDAQ: SRAX) Slated to Host, Present at B. Riley Securities 2021 Vision Day

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies, will be both hosting and presenting at the upcoming B. Riley Securities 2021 Vision Day via its Sequire Virtual Events platform. SRAX, which unlocks data and insights for publicly traded companies through Sequire, its SaaS platform, has been selected as one of B. Riley’s top picks for 2021. The most recent addition to Sequire’s suite of products, the Virtual Events platform provides a way for companies to virtually present to institutional and retail investors. The B. Riley Securities 2021 Vision Day is an invitation-only…

WednesdayJan 13, 2021 11:38 am

QualityStocksNewsBreaks – iClick Interactive Asia Group Limited (NASDAQ: ICLK) Issues Shareholder Letter, Corporate Update

iClick Interactive Asia Group (NASDAQ: ICLK), an independent online marketing and enterprise data solutions provider in China, today announced the release a letter to shareholders from its CEO Jian "T.J." Tang. In the letter, Tang reported success on three targeted milestones, the first of which outlined the company’s improved profitability for its marketing solutions. The update reads, “iClick has realized an adjusted net profit for four quarters in a row due primarily to the business having realized economies of scale and as a result of our efforts with new marketing formats, such as multi-channel networks (‘MCN’), key opinion leaders (‘KOL’)…

WednesdayJan 13, 2021 11:26 am

QualityStocksNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Passes Final Release Tests for Manufacturing Run of Proprietary Immunogene Therapy Treatment

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, announced that it has achieved a significant milestone for its REQORSA(TM) Immunogene Therapy. The company has met all specifications and passed all final release tests for its initial scaled-up, clinical-grade manufacturing run of REQORSA(TM) immunogene therapy. This achievement comes in advance of GNPX’s upcoming Acclaim-1 and Acclaim-2 clinical trials for the treatment of non-small cell lung cancer (“NSCLC”). This announcement also follows the company’s successful completion of the technology transfer of the manufacturing process for the production of REQORSA from the major…

WednesdayJan 13, 2021 11:24 am

QualityStocksNewsBreaks – LexaGene Holdings Inc. (TSXV: LXG) (OTCQB: LXXGF) Initiates Program to Identify UK, South African COVID Sequences

LexaGene Holdings (TSXV: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today announced that it has started a series of studies required by the FDA for Emergency Use Authorization (“EUA”) testing for its COVID-19 assay in a point-of-care (“POC”) environment using its fully automated MiQLab(TM) system. “I’m excited we have progressed to the point where we have started our FDA study. Our open-access technology is unlike any other on the market today, as it could be configured quickly to detect new variants, such as the recent UK variant 1 (aka SARS-CoV-2 VUI 202012/01),”…

WednesdayJan 13, 2021 11:09 am

QualityStocksNewsBreaks – Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) CEO Featured in Exclusive NetworkNewsAudio Interview

Energy Fuels (NYSE American: UUUU) (TSX: EFR) president and CEO Mark Chalmers was featured during a recent NetworkNewsAudio segment. During the interview, the president of the country’s largest producer of uranium and the leading conventional producer of vanadium discussed the company’s newly released sustainability report and its entry into rare earths production. Chalmers noted that the company is starting the new year preparing to enter a new business: the commercial production of rare earth elements (“REE”); the company’s portfolio also includes a pipeline of high-quality, large-scale exploration and development projects. “We are first and foremost a uranium producer, the largest…

WednesdayJan 13, 2021 11:02 am

QualityStocksNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTC: IMEXF) Engages IBN, Builds Momentum for 2021

Imagin Medical (CSE: IME) (OTC: IMEXF), a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures, today announced it has selected the corporate communications expertise of the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities. Under the partnership, IBN will leverage its investor-based distribution network of 5,000+ key syndication outlets, various newsletters, social media channels, wire services via InvestorWire, blogs and other outreach tools to generate greater awareness for Imagin Medical. Like most companies during 2020, Imagin had to adapt to the unexpected circumstances surrounding…

WednesdayJan 13, 2021 10:53 am

QualityStocksNewsBreaks – Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX) Subsidiary, Eye-Net, Partners with Japanese Vehicle Manufacturer for Pilot Project

Foresight Autonomous (NASDAQ: FRSX) (TASE: FRSX), an innovator in automotive vision, announced that its wholly owned subsidiary, Eye-Net Mobile Ltd., is working with the intelligent transport system division of a multibillion-dollar global Japanese vehicle manufacturer to test the Eye-Net(TM) Protect cellular-based V2X (vehicle-to-everything) (“V2X”) accident-prevention solution. The pilot test project is designed to analyze and validate the software development kit (“SDK”) configuration of the Eye-Net solution for possible addition into a smart city project conducted by the vehicle manufacturer. The recently announced pilot test project follows Eye-Net’s August 2020 announcements regarding two additional pilot projects. Eye-Net is partnering with leading…

WednesdayJan 13, 2021 10:32 am

QualityStocksNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Appoints Diabetes, Behavioral Health Experts to Scientific Advisory Board

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, announced the appointment of two renowned experts to its Scientific Advisory Board (“SAB”). Dr. Marilyn Ritholz, psychologist at Joslin Diabetes Center, a Harvard Medical School affiliate, and Dr. David Horwitz, former global chief medical officer of Johnson & Johnson Diabetes Institute, join SAB chairman Eric Milledge; the prestigious board is focused on advancing Dario's technical leadership, helping to guide the development of the company’s bold technology road map and advancing Dario's DTx (“DTx”) platform by integrating members' comprehensive experience and expertise into the company offering. Ritholz and Horwitz are recognized…

WednesdayJan 13, 2021 10:07 am

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Secures $3.074M in Registered Direct Offering

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the closing of its previously disclosed registered direct offering of 3,650,840 shares of its common stock, at a purchase price of $0.842 per share, priced at-the-market under Nasdaq rules. Predictive Oncology secured $3.074 million in gross proceeds from the offering. In a concurrent private placement, Predictive Oncology also issued to the same investors unregistered warrants to purchase up to an aggregate of 1,825,420 shares of common stock at an exercise price of $0.80 per share. H.C. Wainwright & Co.…

WednesdayJan 13, 2021 9:46 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Appears on C3 Chat Show Podcast

CNS Pharmaceuticals (NASDAQ: CNSP) chairman and CEO John Climaco was featured on a recent C3 Chat Show Podcast. The podcast, hosted by Sid Vaidya and Eric Gershey, explores topics related to entrepreneurship, life experiences and best practices. During his interview, Climaco shared the history of CNS Pharmaceuticals and provided an update on the company’s recent business progress, including the fact that the company recently received FDA approval to begin clinical trials studying the company’s lead drug candidate, Berubicin. CNSP is developing Berubicin as a potential treatment for glioblastoma multiforme (“GBM”), an aggressive form of brain cancer currently considered incurable. Climaco called Berubicin…

Site Search

Company Search

Category: QualityStocksNewsBreaks